Patheon Has Made an Initial Public Offering of Ordinary Shares
Patheon has made an initial public offering of 30,487,805 of its ordinary sharesThis figure is...
How to Choose the Right Solubilisation Technology for an API
The proportion of poorly soluble drug compounds in the development pipeline is on the rise, with 70% to 90% of current pipeline drugs falling in the two low-solubility classes of the biopharmaceutical classification system.
With the emergence of new techniques to improve solubility, low solubility compounds are more likely to advance to the clinic.
However, the large spectrum of available technologies can make it challenging for the formulation scientist to proceed in an informed and rational manner.
Download to find out more.
More About This Company
Patheon Signs Flexible Manufacturing Agreement with Amgen
Patheon has announced it has signed a manufacturing agreement with Amgen, one of the world's...
Patheon Selected by Grünenthal to Develop Drugs Using INTAC Abuse Deterrent Formulations Technology
Patheon has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group...
A Cure for Pharmaceutical Supply Chain Complexity
The complexity of drug product supply chains has increased over the last few years mainly...